Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12005-12013

  Shi, Jianxin ^a   Liu, Hongcheng ^b   Yao, Feng ^a   Zhong, Chenxi ^a   Zhao, Heng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell metastasis; Cell migration; MED23; Non small cell lung cancer

Indexed keywords

BETA CATENIN; MED23 PROTEIN; MEDIATOR COMPLEX; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; MED23 PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL GROWTH; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MEDIATOR COMPLEX; MICE; PROTEIN BINDING; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TUMOR BURDEN; TUMOR STEM CELL ASSAY;

EID: 84925286825     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2499-3     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
2. Zheng CX, Zhao SX, Wang P, et al. Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC. Oncol Rep. 2009;22:1057–61.
3. Yin JW, Wang G. The Mediator complex: a master coordinator of transcription and cell lineage development. Development. 2014;141:977–87.
4. Schiano C, Casamassimi A, Rienzo M, de Nigris F, Sommese L, Napoli C. Involvement of Mediator complex in malignancy. Biochim Biophys Acta. 2014;1845:66–83.
5. Carlsten JO, Zhu X, Gustafsson CM. The multitalented Mediator complex. Trends Biochem Sci. 2013;38:531–7.
6. Zhang Y, Xiaoli ZX, Yang F. The Mediator complex and lipid metabolism. J Biochem Pharmacol Res. 2013;1:51–5.
7. Proshkina GM, Shpakovskii GV. The functional interaction of an RNA polymerase II Rpb11 subunit with the Med18 subunit (Srb5) of the Saccharomyces cerevisiae mediator complex]. Bioorg Khim. 2009;35:572–6.
8. Sogaard TM, Svejstrup JQ. Hyperphosphorylation of the C-terminal repeat domain of RNA polymerase II facilitates dissociation of its complex with mediator. J Biol Chem. 2007;282:14113–20.
9. Vijayalingam S, Chinnadurai G. Adenovirus L-E1A activates transcription through mediator complex-dependent recruitment of the super elongation complex. J Virol. 2013;87:3425–34.
10. Vijayalingam S, Chinnadurai G. The other way of stopping: novel role of mediator complex in termination of transcription. J Biol Chem. 2011;286(43):e99969.
11. Mukundan B, Ansari A. Novel role for mediator complex subunit Srb5/Med18 in termination of transcription. J Biol Chem. 2011;286:37053–7.
12. Huang Y, Li W, Yao X, et al. Mediator complex regulates alternative mRNA processing via the MED23 subunit. Mol Cell. 2012;45:459–69.
13. Lin JJ, Lehmann LW, Bonora G, et al. Mediator coordinates PIC assembly with recruitment of CHD1. Genes Dev. 2011;25:2198–209.
14. Yang X, Zhao M, Xia M, et al. Selective requirement for Mediator MED23 in Ras-active lung cancer. Proc Natl Acad Sci U S A. 2011;109:E2813–22.
15. Stevens JL, Cantin GT, Wang G, Shevchenko A, Shevchenko A, Berk AJ. Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science. 2002;296:755–8.
16. Yin JW, Liang Y, Park JY, et al. Mediator MED23 plays opposing roles in directing smooth muscle cell and adipocyte differentiation. Genes Dev. 2012;26:2192–205.
17. Hashimoto S, Boissel S, Zarhrate M, et al. MED23 mutation links intellectual disability to dysregulation of immediate early gene expression. Science. 2011;333:1161–3.
18. Shi J, Han Q, Zhao H, Zhong C, Yao F. Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma. Mol Carcinog. 2013. doi:10.1002/mc.22041.
19. Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008;455:547–51.
20. Malik S, Roeder RG. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev. 2010;11:761–72.
21. Balbin OA, Prensner JR, Sahu A, et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat Commun. 2013;4:2617.
22. Liang JL, Ren XC, Lin Q. Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib. OncoTargets Therapy. 2014;7:761–70.
23. Ahn MJ, Kim SW, Cho BC et al. (2014) Phase II study of afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. The oncologist. 2013–0419. [Epub ahead of print]
24. Han JY, Kim SH, Lee YS, et al. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 2014. doi:10.1016/j.lungcan.2014.04.009.